Abstract: Compounds and compositions are provided as inhibitors of the Wnt/?-catenin pathway for the treatment of diseases that implicate the same.

Abstract: A method of operating a wireless communication device (102) connectable to a communications network is provided. The communications network includes an access node (101, 101-1, 101-2, 101-3). The method includes: monitoring for a plurality of reference signals (121, 122, 123) of a transmission (351) in a plurality of resources, the transmission being provided by the access node (101, 101-1, 101-2, 101-3); and based on said monitoring: participating in positioning of the wireless communication device (102) depending on an indicator indicative of at least one of a magnitude or a phase of at least one first path component (810) of an impulse response (800, 801) of a radio channel, the at least one first path component being associated with at least one reference signal (121, 122, 123) of the plurality of reference signals (121, 122, 123) of the transmission (351).

Abstract: Compounds and compositions are provided as inhibitors of the Wnt/?-catenin pathway for the treatment of diseases that implicate the same.

Abstract: An exhaust aftertreatment apparatus comprising: a) a reactor portion which is tubular and has a flow axis parallel with its longitudinal axis, wherein the reactor portion is configured to receive an exhaust stream in a first end region; b) a mixer located within the reactor portion and located downstream of the first end region, wherein the mixer includes at least a portion of a mixing tube which extends at an angle transverse to the longitudinal axis of the reactor portion; c) an outer tube located about at least a portion of the mixing tube and projecting from an exterior of the reactor portion; and d) an injector in fluid communication with the outer tube and the mixing tube and distanced from the reactor portion, wherein the injector is configured to spray a reductant toward the outer tube and the mixing tube.

Abstract: An exhaust aftertreatment apparatus comprising: a) a reactor portion which is tubular and has a flow axis parallel with its longitudinal axis, wherein the reactor portion is configured to receive an exhaust stream in a first end region; b) a mixer located within the reactor portion and located downstream of the first end region, wherein the mixer includes at least a portion of a mixing tube which extends at an angle transverse to the longitudinal axis of the reactor portion; c) an outer tube located about at least a portion of the mixing tube and projecting from an exterior of the reactor portion; and d) an injector in fluid communication with the outer tube and the mixing tube and distanced from the reactor portion, wherein the injector is configured to spray a reductant toward the outer tube and the mixing tube.

Abstract: Compounds and compositions are provided as inhibitors of the Wnt/beta-catenin pathway and/or activators of the adenosine monophosphate-activated kinase (AMPK) pathway for the treatment of diseases that implicate the same. Such diseases include cancer or a metabolic disease. Cancers that may be treated by these compounds and compositions include adrenocortical cancer, hepatocellular cancer, hepatoblastoma, malignant melanoma, ovarian cancer, Wilm's tumor, Barrett's esophageal cancer, prostate cancer, colon cancer, colorectal cancer, rectal cancer, pancreatic cancer, bladder cancer, breast cancer (e.g. triple negative breast cancer), gastric cancer, head & neck cancer, lung cancer, mesothelioma, cervical cancer, uterine cancer, myeloid leukemia cancer, lymphoid leukemia cancer, pilometricoma cancer, medulloblastoma cancer, glioblastoma, and familial adenomatous polyposis. Metabolic diseases include type 2 diabetes, obesity, hyperlipidemia, alcoholic or non-alcoholic fatty liver disease, and liver fibrosis.

Abstract: Compounds and compositions are provided as inhibitors of the Wnt/?-catenin pathway for the treatment of diseases that implicate the same.

Abstract: A method of operating a wireless communication device (102) connectable to a communications network is provided. The communications network includes an access node (101, 101-1, 101-2, 101-3). The method includes: monitoring for a plurality of reference signals (121, 122, 123) of a transmission (351) in a plurality of resources, the transmission being provided by the access node (101, 101-1, 101-2, 101-3); and based on said monitoring: participating in positioning of the wireless communication device (102) depending on an indicator indicative of at least one of a magnitude or a phase of at least one first path component (810) of an impulse response (800, 801) of a radio channel, the at least one first path component being associated with at least one reference signal (121, 122, 123) of the plurality of reference signals (121, 122, 123) of the transmission (351).

Abstract: Compounds and compositions are provided as inhibitors of the Wnt/?-catenin pathway for the treatment of diseases that implicate the same.

Abstract: The invention relates to prodrugs of anti-cancer and anti-autoimmune diseases therapeutic agents, and methods of making and use thereof.

Abstract: Compounds and compositions are provided as inhibitors of the Wnt/?-catenin pathway for the treatment of diseases that implicate the same.

Abstract: Compounds and compositions are provided as inhibitors of the Wnt/?-catenin pathway for the treatment of diseases that implicate the same.

Abstract: Compounds and compositions are provided as inhibitors of the Wnt/?-catenin pathway for the treatment of diseases that implicate the same.

Abstract: Compounds and compositions are provided as inhibitors of the Wnt/?-catenin pathway for the treatment of diseases that implicate the same.